Therefore, we conclude that OR51E2 represents a promising therapeutic target protein for the treatment of proliferative RPE disorders, such as proliferative vitreoretinopathy (Andrews et al., 1999; Pennock et al., 2014). This evidence concerns the gene OR51E2 and proliferative vitreoretinopathy.